To view this email as a web page, click here.
 
FDA approves first treatment for nonmetastatic CRPC
From our partners at Cancer Network: FDA approved the oral agent apalutamide (Erleada) for the treatment of nonmetastatic castration-resistant prostate cancer.
Read more
 
First direct-to-consumer test for breast cancer risk hits market
FDA approved the first direct-to-consumer test for 3 specific BRCA1/BRCA2 breast cancer gene mutations.
Read more
 
FDA approves breakthrough drug for HIV patients with dwindling options
FDA approved a new drug that offers hope for patients with multidrug-resistant HIV-1 infection.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.